| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14656566.2012.736491 |
| P698 | PubMed publication ID | 23094715 |
| P2093 | author name string | Keith D Lindor | |
| Elizabeth J Carey | |||
| P2860 | cites work | Intrahepatic cholestasis of pregnancy | Q21202971 |
| Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression | Q24336351 | ||
| Bone disease in cholestatic liver disease | Q40560142 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid | Q42620850 | ||
| The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial | Q42947273 | ||
| Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone | Q43086793 | ||
| Dark adaptation in vitamin A-deficient adults awaiting liver transplantation: improvement with intramuscular vitamin A treatment | Q43526345 | ||
| Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients | Q44617739 | ||
| Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem | Q44637688 | ||
| A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis | Q44700430 | ||
| A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results | Q44825279 | ||
| Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial | Q45163892 | ||
| The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis | Q45247238 | ||
| Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study | Q45255372 | ||
| Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial | Q45309693 | ||
| Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study | Q45798330 | ||
| Intrahepatic cholestasis of pregnancy: perinatal outcome associated with expectant management. | Q45970420 | ||
| Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid | Q46102659 | ||
| High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia | Q46174302 | ||
| Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy | Q46687820 | ||
| Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial | Q46714065 | ||
| Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | Q46775425 | ||
| Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study | Q46946947 | ||
| Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo | Q47869512 | ||
| A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis. | Q50623946 | ||
| Calcitriol for bone disease in patients with cirrhosis of the liver. | Q50648822 | ||
| Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid | Q51636366 | ||
| Diagnosis and management of primary sclerosing cholangitis. | Q51726466 | ||
| Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. | Q51736133 | ||
| Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. | Q53502601 | ||
| Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. | Q54032405 | ||
| EASL Clinical Practice Guidelines: management of cholestatic liver diseases. | Q55051951 | ||
| Primary biliary cirrhosis | Q56428273 | ||
| Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy | Q57825376 | ||
| High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis | Q24655731 | ||
| Guidelines on the management of osteoporosis associated with chronic liver disease | Q24685899 | ||
| Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II) | Q28193306 | ||
| High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis | Q28237152 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid | Q28284404 | ||
| The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus | Q33280833 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Diagnosis and management of autoimmune hepatitis | Q34118165 | ||
| Farnesoid X receptor agonists for primary biliary cirrhosis | Q34162898 | ||
| An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis | Q34608494 | ||
| Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience | Q34904107 | ||
| Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years | Q34932835 | ||
| The epidemiology of primary biliary cirrhosis | Q35573904 | ||
| Systematic review: ursodeoxycholic acid--adverse effects and drug interactions | Q35583064 | ||
| Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. | Q35594405 | ||
| Intestinal failure-associated liver disease: what do we know today? | Q36394236 | ||
| Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis | Q36495172 | ||
| Primary sclerosing cholangitis: summary of a workshop | Q36581592 | ||
| Survival and dependence on home parenteral nutrition: experience over a 25-year period in a UK referral centre | Q36609902 | ||
| Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses | Q36801651 | ||
| Intestinal failure-associated liver disease: management and treatment strategies past, present, and future | Q36903646 | ||
| Ursodiol in patients with parenteral nutrition-associated cholestasis. | Q36958168 | ||
| The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study | Q37024748 | ||
| Update on the treatment of the pruritus of cholestasis | Q37074732 | ||
| Immunoglobulin G4-associated cholangitis | Q37137399 | ||
| Recent advances in the management of intestinal failure-associated liver disease | Q37429569 | ||
| Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. | Q37538088 | ||
| Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis | Q37738636 | ||
| Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue | Q37808546 | ||
| New treatment strategies for primary sclerosing cholangitis | Q37892297 | ||
| 'Out-patient' albumin dialysis for cholestatic patients with intractable pruritus | Q38460458 | ||
| Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. | Q38467441 | ||
| Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy | Q39891944 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacotherapy | Q701216 |
| P304 | page(s) | 2473-2484 | |
| P577 | publication date | 2012-10-24 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Current pharmacotherapy for cholestatic liver disease | |
| P478 | volume | 13 |
| Q37663363 | All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice |
| Q42623395 | Bile acids induce arrhythmias: old metabolite, new tricks |
| Q42318815 | Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response |
| Q39639612 | Chlorogenic acid inhibits cholestatic liver injury induced by α-naphthylisothiocyanate: involvement of STAT3 and NFκB signalling regulation. |
| Q64987469 | Effect of combined ursodeoxycholic acid and glucocorticoid on the outcome of Kasai procedure: A systematic review and meta-analysis. |
| Q24187279 | Interventions for treating intrahepatic cholestasis in people with sickle cell disease |
| Q24200803 | Interventions for treating intrahepatic cholestasis in people with sickle cell disease |
| Q38651517 | Interventions for treating intrahepatic cholestasis in people with sickle cell disease. |
| Q36962101 | Protective Effects of Guava Pulp on Cholestatic Liver Injury |
| Q40228314 | Protective effect of Calculus Bovis Sativus on intrahepatic cholestasis in rats induced by α-naphthylisothiocyanate |
| Q36960966 | Therapeutic targets for cholestatic liver injury |
| Q59808161 | Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES) |
| Q92394852 | Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial |
Search more.